TC
ABBV icon

TFR Capital’s AbbVie ABBV Stock Holding History

TFR Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Sell
16,506
-1,010
-6% -$217K 1.17% 20
2026
Q1 		$3.81M Buy
17,516
+400
+2% +$88.7K 1.17% 23
2025
Q4 		$3.91M Buy
17,116
+717
+4% +$163K 1.3% 19
2025
Q3 		$3.8M Buy
16,399
+825
+5% +$168K 1.27% 18
2025
Q2 		$2.89M Buy
15,574
+352
+2% +$65.4K 1.05% 21
2025
Q1 		$3.19M Buy
15,222
+2,038
+15% +$396K 1.33% 19
2024
Q4 		$2.34M Buy
+13,184
New +$2.42M 1.16% 23

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TFR Capital's ABBV Position: Q2 2026 in Review

TFR Capital reduced its AbbVie (ABBV) stake by 5.8% in Q2 2026, selling an estimated $217K and leaving 16,506 shares worth $4.15M. The position accounts for 1.17% of the portfolio, ranked #20.

TFR Capital first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • TFR Capital held 16,506 shares of AbbVie worth $4.15M as of Q2 2026.
  • TFR Capital sold 1,010 AbbVie shares in Q2 2026, an estimated $217K.
  • AbbVie made up 1.17% of TFR Capital's portfolio in Q2 2026, its #20 holding.
  • TFR Capital first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TFR Capital's 13F filing for Q2 2026, filed 6 Aug 2026.